Can I Take Omega-3 (EPA/DHA) with Cytomel (Liothyronine)?

What Is the Interaction Between Omega-3 and Liothyronine?

The short answer is that no pharmacokinetic interaction between omega-3 fatty acids (EPA/DHA) and liothyronine has been confirmed in peer-reviewed literature. The two substances do not meaningfully compete for the same absorption transporters or metabolic enzymes. What does exist is a pharmacodynamic overlap: both agents influence triglyceride metabolism, and high-dose omega-3 adds a mild antiplatelet effect that could matter if you are already on blood-thinning medications.

Liothyronine is a synthetic form of triiodothyronine (T3), the active thyroid hormone. It is prescribed as brand-name Cytomel or in generic form, typically at doses ranging from 5 mcg to 60 mcg per day, either alone or alongside levothyroxine (T4). Omega-3 supplements contain eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or both, derived from fish oil, algal oil, or krill oil.

Pharmacokinetic Reality: No Absorption Conflict

Liothyronine is absorbed in the small intestine. Its absorption is known to be affected by certain compounds, particularly calcium, iron, antacids, and bile-acid sequestrants, which bind thyroid hormone directly in the gut. The FDA prescribing information for Cytomel does not list omega-3 fatty acids among substances that reduce absorption. EPA and DHA are fatty acids absorbed via the lymphatic system through chylomicron formation, a pathway that does not intersect meaningfully with thyroid hormone transport proteins.

So you do not need to separate your omega-3 capsule from your Cytomel dose by a fixed window the way you would with calcium or iron supplements.

Pharmacodynamic Overlap: The Triglyceride Connection

This is the clinically meaningful part of the interaction. T3, acting through thyroid hormone receptors on hepatocytes, increases the expression of LDL receptors and stimulates fatty acid oxidation, which lowers circulating triglycerides and LDL cholesterol. Research published in Endocrinology confirms that T3 directly regulates hepatic lipid metabolism genes. Separately, EPA and DHA at doses of 2-4 g/day reduce triglycerides by 20-30% through inhibition of VLDL synthesis and increased fatty acid beta-oxidation, as shown in the REDUCE-IT trial population analyses.

When you take both, the triglyceride-lowering effects stack. For most women this is not dangerous. In fact, for perimenopausal and postmenopausal women with dyslipidemia, the additive effect may be clinically useful. The caution applies if your liothyronine dose is already driving your triglycerides very low and you add high-dose prescription omega-3 (icosapentaenoic acid, 4 g/day as in Vascepa). Hypertriglyceridemia at the extremes is rarely a practical concern here, but your clinician should review your lipid panel after adding either agent.

The Antiplatelet Question

EPA and DHA at higher doses (generally above 3 g/day EPA+DHA combined) have a mild antiplatelet effect, reducing platelet aggregation by competing with arachidonic acid in the thromboxane synthesis pathway. A 2022 meta-analysis in JAMA Cardiology found that high-dose omega-3 increased atrial fibrillation risk and was associated with minor bleeding events at doses used therapeutically (4 g/day EPA). Liothyronine itself does not have an antiplatelet mechanism. However, hyperthyroidism or supraphysiologic T3 levels can increase heart rate and, in susceptible women, trigger arrhythmias. The combination does not directly amplify antiplatelet activity, but if you are also taking warfarin, aspirin, or another anticoagulant, your prescriber needs to know your omega-3 dose.

At typical supplement doses of 1-2 g/day combined EPA+DHA, the antiplatelet effect is minimal and not a contraindication.

How Thyroid Physiology Differs Across a Woman's Life Stages

Your thyroid status is not static. Hormonal shifts across your reproductive life directly affect how much T3 you need, how your labs read, and whether symptoms change. Understanding this helps you catch dosing issues before they compound.

Reproductive Years (Ages 18-40)

The menstrual cycle affects thyroid hormone binding. Estrogen raises thyroid-binding globulin (TBG), the protein that carries thyroid hormone in the bloodstream. Higher TBG means more hormone is "bound" and unavailable, which can make some women feel undermedicated in the luteal phase even with a stable dose. Free T3 (the active fraction) is what matters clinically, and your prescriber should order free T3 rather than total T3 when monitoring liothyronine therapy.

Women with PCOS have a higher prevalence of autoimmune thyroid disease (Hashimoto's thyroiditis) than the general population. A 2019 study in Frontiers in Endocrinology found that Hashimoto's thyroiditis co-occurs in up to 27% of women with PCOS. If you are on liothyronine for hypothyroidism driven by Hashimoto's, omega-3 supplementation may offer an anti-inflammatory secondary benefit. A small randomized trial in the Journal of Clinical Endocrinology and Metabolism found that EPA/DHA supplementation reduced inflammatory markers in autoimmune thyroid conditions, though sample sizes were small and this is not a replacement for thyroid medication.

Trying to Conceive and Pregnancy

Liothyronine in pregnancy requires special attention. Read this section carefully.

The standard of care for hypothyroidism in pregnancy is levothyroxine (T4), not liothyronine (T3). The reason is physiological: T4 crosses the placenta and is converted to T3 locally in fetal tissues as needed. Liothyronine (T3) crosses the placenta poorly, meaning a fetus dependent on maternal T3 supply may be inadequately supported. ACOG and the American Thyroid Association guidelines state that if a woman is on liothyronine and becomes pregnant, she should be transitioned to levothyroxine or a T4/T3 combination under close endocrinology supervision, with TSH targets of 0.1-2.5 mIU/L in the first trimester.

Liothyronine is listed as Pregnancy Category A at replacement doses in older FDA classification, meaning controlled studies have not shown fetal risk at physiologic doses. However, supraphysiologic T3 carries real risk to the pregnancy.

Omega-3 (DHA specifically) is not only safe in pregnancy but actively recommended. ACOG recommends 200-300 mg DHA daily during pregnancy to support fetal neural development. Combining DHA supplementation with thyroid replacement (ideally transitioned to levothyroxine) poses no known interaction risk.

If you are trying to conceive and currently take liothyronine: speak with your OB-GYN or reproductive endocrinologist about transitioning to levothyroxine before conception. Uncontrolled hypothyroidism raises miscarriage risk significantly.

Postpartum and Lactation

Liothyronine transfers into breast milk in small amounts. Data from the NIH LactMed database indicates that T3 concentrations in breast milk are low and that breastfed infants of mothers on replacement-dose liothyronine do not show thyroid hormone excess. Monitoring the infant's thyroid function is recommended if doses are supraphysiologic.

Postpartum thyroiditis affects approximately 5-10% of women in the year after delivery. This condition can cause a hyperthyroid phase followed by a hypothyroid phase, sometimes leading to a short-term prescription for thyroid hormone. Adding omega-3 during the postpartum period is generally safe and may support mood, given the well-documented association between postpartum depression and low omega-3 status. A Cochrane review found EPA-dominant omega-3 supplementation associated with modest antidepressant effects, though evidence specifically in postpartum populations remains limited.

Perimenopause and Menopause

Perimenopausal women face compounding metabolic shifts. Estrogen withdrawal reduces LDL receptor activity, raises LDL and triglycerides, and increases cardiovascular risk. If you are already on liothyronine and entering perimenopause, your thyroid dosing may need recalibration as TBG levels fall with declining estrogen. Adding omega-3 at this life stage may meaningfully support the lipid profile alongside your thyroid medication.

The Menopause Society (NAMS) does not list omega-3 as contraindicated with thyroid medications, but notes that high-dose fish oil should be discussed with your provider if you are on medications affecting clotting or lipid metabolism.

Postmenopausal women on liothyronine should also monitor bone density. Supraphysiologic T3 is associated with accelerated bone turnover and a higher fracture risk. Omega-3 has a modest bone-protective association in observational data, though it does not compensate for T3-induced bone loss if dosing is excessive.

Who This Combination Is Appropriate For and Who Should Be Cautious

The decision to take omega-3 alongside liothyronine is not one-size-fits-all. Here is a clinical decision framework organized by life stage and condition.

Women Who Can Generally Proceed With Standard Monitoring

• Women on stable liothyronine replacement (not suppression) doses with normal free T3 and TSH
• Women with PCOS and autoimmune thyroiditis who want anti-inflammatory support
• Perimenopausal and postmenopausal women with elevated triglycerides taking standard supplement doses (1-2 g EPA+DHA/day)
• Women not on anticoagulants or antiplatelet drugs
• Pregnant women on omega-3 (DHA): safe and recommended, but transition liothyronine to levothyroxine first

Women Who Should Discuss With Their Prescriber Before Starting Omega-3

• Women on liothyronine doses above 25 mcg/day who also have cardiac arrhythmia history
• Women taking warfarin, clopidogrel, or aspirin alongside liothyronine
• Women considering high-dose prescription omega-3 (icosapentaenoic acid 4 g/day or mixed EPA/DHA at similar doses)
• Women with a history of atrial fibrillation, given the signal from the REDUCE-IT trial that high-dose icosapentaenoic acid raised AF risk by approximately 1.5-fold compared to mineral oil placebo
• Women with significant hepatic impairment, where both T3 metabolism and fatty acid clearance may be altered

Women Who Should Delay or Avoid

• Women currently pregnant on liothyronine: the priority is transitioning to levothyroxine, not adding supplements without oversight
• Women with known hyperthyroid symptoms (palpitations, tremor, weight loss) on their current liothyronine dose: adding triglyceride-lowering agents without addressing the dose first is not appropriate

Dosing and Timing Guidance

No fixed separation window is required between omega-3 and liothyronine. This is a meaningful difference from supplements like calcium, iron, or certain antacids, which should be taken four hours apart from thyroid hormone to prevent chelation.

Practical Timing

Take liothyronine on an empty stomach, typically 30-60 minutes before breakfast, as recommended in the Cytomel prescribing information. Take your omega-3 capsule with a meal, ideally lunch or dinner, to reduce fishy aftertaste and GI discomfort and to maximize absorption of fat-soluble EPA and DHA through the dietary fat present in the meal. These two timing recommendations are naturally compatible and do not conflict.

Omega-3 Doses Relevant to This Discussion

| Dose Range | Form | Interaction Concern | |---|---|---| | 250-500 mg EPA+DHA/day | Standard dietary supplement | Minimal; no monitoring beyond routine labs | | 1-2 g EPA+DHA/day | Higher-dose supplement | Mild triglyceride lowering; check lipid panel at 3 months | | 2-4 g EPA+DHA/day | Therapeutic / prescription range | Antiplatelet effect and AF signal; requires clinical review with liothyronine prescriber |

Monitoring Plan

After starting omega-3 alongside liothyronine, a reasonable monitoring schedule includes:

• Free T3, free T4, and TSH at your next scheduled thyroid check (or within 6-8 weeks if adding omega-3 changes other medications)
• Fasting lipid panel at baseline and 3 months after adding omega-3
• Report any new palpitations, unusual bruising, or bleeding symptoms to your prescriber promptly

Pregnancy and Lactation Safety

REQUIRED READING if you are pregnant, planning pregnancy, or breastfeeding.

Liothyronine in Pregnancy

Liothyronine (T3) is classified as Pregnancy Category A at replacement doses. However, T3 crosses the placenta poorly compared to T4. The American Thyroid Association and ACOG jointly recommend levothyroxine, not liothyronine, as the thyroid hormone of choice during pregnancy, because the placenta converts T4 to T3 locally as the fetal brain and organ systems require it. If you become pregnant while on liothyronine, contact your prescriber immediately for a transition plan. Untreated or undertreated hypothyroidism in pregnancy is associated with miscarriage, preterm birth, and neurodevelopmental deficits in the child.

Contraception note: liothyronine is not a teratogen at replacement doses, so it does not require a mandatory contraception protocol the way drugs like warfarin or isotretinoin do. Still, if you are taking supraphysiologic doses for thyroid suppression therapy, discuss your family-planning intentions with your endocrinologist before conception.

Omega-3 in Pregnancy

DHA is actively recommended during pregnancy for fetal neurodevelopment. ACOG supports at least 200 mg DHA daily for pregnant women. Most prenatal vitamins do not contain enough DHA, so a separate algal-oil or fish-oil DHA supplement is commonly added. There is no interaction between omega-3 and levothyroxine (the preferred thyroid drug in pregnancy) at standard supplement doses.

Lactation

Liothyronine transfers into breast milk in small quantities. LactMed rates maternal thyroid replacement as generally compatible with breastfeeding when used at standard replacement doses. Omega-3, particularly DHA, is present naturally in breast milk and supplementing it increases DHA content in milk, which may support infant brain development. No interaction between the two in the context of lactation has been identified.

Evidence Gaps and What We Do Not Know

The honest answer is that no dedicated randomized controlled trial has examined the liothyronine-plus-omega-3 combination directly in women. The interaction characterization above is built from:

1. Mechanism studies on how T3 and omega-3 each affect hepatic lipid metabolism
2. Pharmacokinetic data on thyroid hormone absorption (which does not implicate omega-3)
3. Clinical antiplatelet data on high-dose omega-3 from large cardiovascular trials (REDUCE-IT, STRENGTH)
4. Expert consensus from Natural Medicines interaction databases (rated "minor" interaction level for omega-3 with thyroid hormones)

Women are underrepresented in many of the cardiovascular and lipid trials that inform omega-3 dosing recommendations. The REDUCE-IT trial enrolled 27.7% women. The STRENGTH trial, which used a mixed EPA/DHA formulation and found no cardiovascular benefit, had similar female representation. Sex-specific subgroup analyses from these trials are underpowered. This means the antiplatelet and AF risk data for omega-3 at high doses comes primarily from predominantly male populations, and the true risk in women on thyroid replacement specifically has not been characterized.

This is a genuine evidence gap. Until sex-stratified data exists, the conservative clinical approach for women on liothyronine who want to take omega-3 above 2 g/day EPA+DHA is to review it with their prescriber, especially if they have any cardiac history.

What to Tell Your Provider

When you bring this question to your thyroid prescriber or OB-GYN, be specific. Tell them:

• The exact dose of liothyronine you take (mcg per day) and whether you also take levothyroxine
• The form of omega-3 you plan to use (fish oil, algal oil, krill oil), the brand, and the EPA and DHA amounts per serving listed on the label
• Your current lipid panel results if available
• Any other medications that affect clotting (aspirin, NSAIDs, blood thinners)
• Your reproductive status: actively trying to conceive, pregnant, postpartum, perimenopausal, or postmenopausal

A 2021 analysis in Menopause journal found that supplement use among menopausal women is highly prevalent but frequently undisclosed to prescribers. Bringing your supplement list to every thyroid appointment is not optional paperwork; it is the information your prescriber needs to dose you accurately.

Your next step: at your next scheduled free T3 and TSH check, bring your omega-3 label and ask your provider to note the supplement in your medication list. If your triglycerides are currently elevated, ask about a baseline lipid panel before starting omega-3 so you can see the actual effect.